MyopiaX Blue-Light VR Trial Fell Short of DIMS Lenses

Blue light has become the cartoon villain of childhood myopia: screens emit it, children use screens, and myopia rates have risen. MyopiaX turns that story inside out. The smartphone-paired VR headset delivers blue light as a treatment, aiming it at the optic nerve head—the retinal blind spot—rather than at the image-forming retina.

It is an inventive biological hypothesis. It is not, so far, an effective myopia treatment. In its first multicenter randomized trial, children assigned to MyopiaX had 0.14 mm of axial-length growth over six months, versus 0.08 mm with DIMS myopia-control spectacles: 75% more growth in the experimental arm. The difference in spherical equivalent refraction was small: −0.18 D with MyopiaX versus −0.16 D with DIMS lenses. The trial established short-term device safety, but it did not show that MyopiaX controlled myopia better than an established optical intervention.

A clever mechanism meets an unfavorable clinical result

Loughman et al.'s 2025 MyopiaX-1 trial randomized 124 children with juvenile myopia in a 2:1 ratio to the MyopiaX device or DIMS (Defocus Incorporated Multiple Segments) spectacle lenses. The primary efficacy analysis included 101 participants. Another 23 had enrolled under an earlier sham-controlled version of the protocol and contributed only safety data after the investigators changed the design in October 2022.

Children in the device group used the headset for 10 minutes daily. It delivered 464 nm blue light at 60 melanopic lux, flickering at 15 Hz, to the optic nerve head. The proposed target is melanopsin-expressing intrinsically photosensitive retinal ganglion cells, or ipRGCs, which may communicate with dopamine-producing retinal cells. Dopamine has plausible links to eye-growth regulation, and outdoor light exposure has epidemiologic support as protection against myopia onset and progression.

The distinction matters. MyopiaX does not simply recreate bright outdoor light, and its theory does not require blue light across the retina to be beneficial. It proposes a targeted melanopsin pathway at the blind spot. Earlier human experiments cited in the trial found that one 60-second exposure produced 6.2 μm of subfoveal choroidal thickening and a 6.8 μm shortening in axial length. Those are acute biomarker responses, not evidence that a child's eye will grow more slowly over months. The six-month randomized result did not bridge that gap.

Axial length is the endpoint that deserves the most attention because myopia progression reflects elongation of the eye. At six months, MyopiaX trailed DIMS lenses by 0.06 mm in axial growth. The refractive results were nearly the same, but that does not erase the axial-length result; the two measurements capture related but distinct aspects of myopia progression. The publication's reported findings provide no superiority, noninferiority, or parity result for MyopiaX against DIMS.

The screen-blue-light story remains unproven

Screen time and myopia often travel together, especially during periods of more indoor living and intensive near work. That observation does not identify blue light as the cause. Children who spend more time on screens may spend less time outdoors, perform more sustained near work, and have altered sleep or circadian patterns. Those variables can move together so tightly that blaming a single wavelength becomes more slogan than science.

No controlled finding here isolates screen-emitted blue light as an independent cause of myopia. The MyopiaX rationale is therefore more specific than the evidence behind the popular claim that "blue light causes myopia." A targeted blue-light intervention can still be worth testing without proving that ordinary screen blue light caused the problem. But the causal premise should not be presented as settled.

Why red-light therapy is a relevant—but imperfect—comparison

Repeated low-level red-light therapy (RLRL) has a far larger clinical evidence base than MyopiaX. Multiple systematic reviews and meta-analyses report less axial elongation with RLRL than with untreated or single-vision control groups, including a 2023 meta-analysis of randomized trials, a 2024 systematic review and meta-analysis, and a 2025 review. Those pooled results support a short- to medium-term efficacy signal for RLRL, although questions about protocol, durability after stopping treatment, and long-term safety remain.

A 2025 network meta-analysis by Zheng et al. found RLRL comparable to or more effective than orthokeratology and 0.01% atropine for axial-length control. That comparison does not make RLRL and MyopiaX interchangeable. They use different wavelengths, delivery methods, and doses. MyopiaX's retinal irradiance was about 61 μW/cm²; the RLRL range cited in MyopiaX-1 was 8.0×10⁴ to 7.2×10⁶ μW/cm². Even the low end of that red-light range exceeds MyopiaX by more than 1,000-fold.

Both approaches have invoked choroidal responses, but a shared biomarker does not prove equivalent treatment effects. In a 2023 longitudinal RLRL study, choroidal-thickness trajectories predicted longer-term treatment response. A 2026 multicenter cohort study of 538 children receiving RLRL likewise identified early axial and choroidal changes as useful predictors of one-year response. These findings make choroidal thickness scientifically interesting. They do not turn MyopiaX's one-minute biomarker response into proof of durable benefit.

What the trial can and cannot answer

MyopiaX-1 had real strengths. It was multicenter, randomized, and used an active comparator rather than a passive one. No serious adverse events attributable to MyopiaX occurred over six months. For a first-in-class device, that is useful information.

Its limitations are equally important. The protocol change removed the untreated reference arm from the primary efficacy analysis, so the trial cannot estimate MyopiaX's absolute effect against no treatment. It can say that MyopiaX performed worse than DIMS in this study. The device intervention was single-masked: participants knew their assignment, which can affect adherence and behavior in a daily, home-based treatment. The 2:1 randomization favored the device arm to collect safety data, leaving fewer children in the DIMS group for the efficacy comparison.

Six months also cannot answer whether any effect would persist, strengthen, or reverse over years. During months 7 through 12, MyopiaX participants also received DIMS lenses, which prevents a clean longer-term assessment of the device alone. The trial publication does not provide an independent benchmark for whether the DIMS group's 0.08 mm six-month progression matched expected performance in this population. Finally, Dopavision GmbH developed MyopiaX and loaned the VR hardware; that sponsorship does not invalidate the measurements, but it raises the bar for independent replication.

The practical verdict

Do not choose MyopiaX as a myopia-control treatment on the evidence now available. Its only multicenter randomized trial found more axial elongation than DIMS lenses at the primary six-month endpoint, while showing only short-term safety and acute mechanistic signals.

Families should discuss established myopia-management options with a pediatric eye-care clinician. Outdoor time remains the best-supported behavioral measure for prevention, while optical strategies, orthokeratology, and atropine have established clinical roles. RLRL has encouraging pooled evidence, but its longer-term safety and durability still need scrutiny. MyopiaX needs a well-powered, sham-controlled trial with a positive clinical endpoint before its blind-spot blue-light theory earns a place beside those options.